Th1/Th2 CD4+ T cell responses against NY-ESO-1 in HLA-DPB1*0401/0402 patients with epithelial ovarian cancer

Cancer immunity

Sacha Gnjatic²  Feng Qian¹ 

[1] Department of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY, USADepartment of Immunology, Roswell Park Cancer Institute, Buffalo, NY, USADepartment of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY, USADepartment of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY, USADepartment of Immunology, Roswell Park Cancer Institute, Buffalo, NY, USADepartment of Immunology, Roswell Park Cancer Institute, Buffalo, NY, USADepartment of Gynecologic Oncology, Roswell Park Cancer Institute, Buffalo, NY, USADepartment of Immunology, Roswell Park Cancer Institute, Buffalo, NY, USA;Ludwig Institute for Cancer Research, New York Branch at Memorial Sloan-Kettering Cancer Center, New York, NY, USALudwig Institute for Cancer Research, New York Branch at Memorial Sloan-Kettering Cancer Center, New York, NY, USALudwig Institute for Cancer Research, New York Branch at Memorial Sloan-Kettering Cancer Center, New York, NY, USA

关键词: human;    ovarian cancer;    NY-ESO-1;    humoral immunity;    cellular immunity;   

DOI  :  

学科分类：肿瘤学

来源: Cancer immunity

【 授权许可】

Unknown